Interview with Steven Yatomi-Clarke CEO and Managing Director, Prescient Therapeutics

(17:59)

Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials

(2:10)

Prescient Therapeutics (ASX: PTX) OmniCAR Explainer

(2:35)

Prescient Therapeutics (ASX:PTX) CEO interview

(15:39)

Prescient Therapeutics PTX-100 shows promising results in Phase 1b study

(7:28)

Prescient Therapeutics

(9:32)

Prescient Therapeutics

(15:32)

Chimeric Therapeutics CEO discusses progress with promising cancer treatment trials

(4:40)

Prescient Therapeutics

(12:33)

Prescient Therapeutics

(13:26)

Prescient Therapeutics (ASX: PTX)

(7:43)

Prescient Therapeutics furthers development of novel anti-cancer targeted therapies

(25:16)

Prescient Therapeutics is developing novel personalised therapies against a range of cancers

(18:29)

Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference

(4:28)

Prescient Therapeutics announces share purchase plan to raise $8 million

(3:13)

Prescient Therapeutics PTX Finance News Network

(13:44)

Prescient Therapeutics Special Update: CellPryme-M Platform

(49:49)

Prescient Therapeutics is making game-changing cancer therapies for a global market

(9:15)